Response Rates and Adverse Event Rates in Phase II Trial

Slides:

Advertisements

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Advertisements

Palumbo A et al. Proc ASH 2013;Abstract 536.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.

Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.

Highlights in the Management of Breast Cancer Nanoparticles incapsulated drugs Alessandra Fabi Medical Oncology Rome, 10 May 2013 Mediterranean School.

Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

A Phase III Study (EMBRACE) of Eribulin Mesylate versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Pritchard KI et al. Proc SABCS 2010;Abstract P

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

1 Albumin-Bound Paclitaxel for the Treatment of Non-small Cell Lung Cancer Monotherapy Studies.

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes:

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Slideset on: Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

BACKGROUND & STUDY AIMS TARGETED CHEMOTHERAPY WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR METASTATIC BREAST CANCER (MBC): WHICH BENEFIT FOR WHICH.

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.

EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed.

Istituto Oncologico Veneto IRCCS

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

Alessandra Gennari, MD PhD

Palumbo A et al. Proc ASH 2012;Abstract 200.

Chicago 2008: Post - ASCO Analysis: Metastatic Breast Cancer

Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.

Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Mateos MV et al. Proc ASH 2013;Abstract 403.

CCO Independent Conference Coverage

Swain SM et al. Proc SABCS 2012;Abstract P

Ruolo di carboplatino + nab-paclitaxel nel trattamento di I linea nel carcinoma polmonare non a piccole cellule P.Bidoli S.C. Oncologia Medica.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Erba HP et al. Blood 2008;112: Abstract 558

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

The nab-Paclitaxel Difference

Barrios C et al. SABCS 2009;Abstract 46.

Nab-paclitaxel nel NSCLC avanzato

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Baselga J et al. SABCS 2009;Abstract 45.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES

Advani RH et al. Proc ASH 2011;Abstract 443.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Nab-paclitaxel: lo stato dell’arte

Presentation transcript:

Response Rates and Adverse Event Rates in Phase II Trial % 100 mg/m2qw, 3/4wks 150 mg/m2qw, 3/4wks 100 mg/m2q3w Nab-paclitaxel docetaxel Adapted from Gradishar et al. EBCC-6 2008, abstract 409.

Subset Analysis of Phase II CA-024 Trial and Phase III CA-012 Trial Every three weeks Weekly 300 mg/m2 n=76 260 mg/m2 n=229 150 mg/m2 n=74 100 mg/m2 Received as first-line therapy (%) 100 43 ORR (%) 46 33 74 63 Median PFS, months 10.9 5.2 14.6 7.5 Median OS, months NA 14.9 Grade 4 neutropenia (%)* 5 9 Grade 3 peripheral neuropathy (%) 17 10 14 8 Data from CA-012 were previously reported (Gradishar et al. J Clin Oncol 2005;23:7794-803). NA: Not available because data not yet mature for phase II study. *Grade 4 neutropenia based on central laboratory data. Adapted from O’Shaughnessy et al. EBCC-6 2008, abstract 416.